Opendata, web and dolomites


A disruptive Magnetically Enhanced Library preparation platform for Next Generation Sequencing

Total Cost €


EC-Contrib. €






 MAGELIA project word cloud

Explore the words cloud of the MAGELIA project. It provides you a very rough idea of what is the project "MAGELIA" about.

reagents    expensive    scientists    institut    struggle    clinicians    2021    cnrs    2016    awards    accelerating    instrument    ground    sme    trl8    grants    commercialization    first    platforms    sequencing    inorevia    biotech    revolution    genomics    fast    library    trl6    curie    ignite    leader    round    prototype    france    spin    biology    finish    ten    billion    customers    pharmacy    ready    miniaturised    smaller    series    accelerate    earlier    business    faster    persons    labs    initiate    democratise    succeed    medicine    board    renowned    automated    tackle    inception    biologists    400    team    upstream    rights    advisory    patents    exclusive    meet    won    medium    market    volumes    turnover    ngs    paris    cheaper    generation    manual    secured    throughput    times    microfluidics    15    company    tool    holds    talents    samples    magelia    entirely    preparations    platform    engineers    1000    raw    put    biological    leverages    preparation    scarce    seed    backed    breaking    reproducibility    off    larger    modern    companies    confirmed    miniaturized   

Project "MAGELIA" data sheet

The following table provides information about the project.


Organization address
address: 6 RUE JEAN CALVIN
city: PARIS
postcode: 75005
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 2˙793˙000 €
 EC max contribution 1˙955˙100 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2021-07-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INOREVIA FR (PARIS) coordinator 1˙955˙100.00


 Project objective

Inorevia is a spin-off from the Institut Curie/CNRS (Paris) that leverages over ten years of research in microfluidics to tackle challenges of modern Biology and Medicine with faster, cheaper, miniaturised sample preparation. Inorevia’s ground-breaking biology platform, the MAGELIA, will provide Biologists and Clinicians with a unique tool to efficiently process raw biological samples upstream of advanced analysis methods such as Next-Generation Sequencing (NGS) in volumes 100 to 1000 times smaller, in an entirely automated platform. After over 2 years of R&D and a first TRL6 prototype of the MAGELIA platform, Inorevia is ready to accelerate its development to reach TRL8, finish the development of the MAGELIA and initiate its commercialization by 2021. Aiming for the NGS sample preparation market, this first generation of the MAGELIA platform will meet the needs of low to medium throughput labs, sequencing platforms, biotech and pharmacy companies, who struggle with low-reproducibility manual library preparations, expensive reagents, and scarce biological samples. The MAGELIA platform will democratise NGS to ignite a revolution in genomics on a fast-growing 8 Billion € market. To succeed, Inorevia has put together an 8 persons’ team of recognized scientists, engineers, and confirmed business talents, backed by a renowned advisory board. The company holds exclusive rights on 4 key patents and large know-how. Since its inception in 2016, Inorevia has won several renowned awards in France and Europe, secured over 1.3 M€ in grants and a seed round. The MAGELIA SME Instrument Phase 2 project specifically aims at accelerating Inorevia’s go-to market through faster development, earlier pre-series and larger market reach in Europe. With the objective to reach over 400 customers and 15% of the European market within five years, with a turnover of 30 M€, INOREVIA will become the European leader in miniaturized samples preparation for modern biology and medicine.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MAGELIA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MAGELIA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

CoLumbo (2019)


Read More  

ClosedToe (2020)

Sock toe closing system for circular knitting machines

Read More  


Flame Detector Based on Epitaxial Metal Oxides (EMO) Technology

Read More